Buy Full Version
"Medical Contrast Agent Market"

Let us help you !

Invalid Email.

Please Select Country.

Invalid contact no.

Special Symbols Not Allowed.

Invalid Security Code.

Thank You For Your Interest.

We've Successfully Got Your Message,

Our Executive will get back to you Shortly.

Medical Contrast Agent Market by Type (Barium-based Contrast Media, Iodinated Contrast Media, Gadolinium-based Contrast Media, and Microbubble Contrast Media), Procedure (X-ray/Computed Tomography (CT), Magnetic Resonance Imaging (MRI), and Ultrasound), Route of Administration (Oral Contrast Media, Injectable Contrast Media, Rectal Contrast Media, and Urethral Contrast Media), Indication (Cardiovascular Disorders, Oncology, Gastrointestinal Disorders, Musculoskeletal Disorders, Neurological Disorders, and Nephrological Disorders), and Application (Radiology, Interventional Radiology, and Interventional Cardiology) - Global Opportunity Analysis and Industry Forecast, 2019-2026

Healthcare	LI_184367	Pages: NA	Dec 2019 \| 1466 Views
Author(s) : NA	Tables: NA	Charts: NA	Formats*:

Medical contrast agent is a material used in medical imaging to improve the contrast of structure or fluids inside a body. The contrast agents provide enhanced visibility for observation of blood vessels and the gastrointestinal tract. According to the imaging modalities such as x-ray and ultrasound, an array of contrast reagents is used as per requirement of the imaging technique.

The medical contrast agent market is driven by growth in approval of contrast agents and increase in number of private diagnostics clinics & services. Moreover, technological development in diagnostics imaging and strong product pipeline of market players are expected to boost the market growth. However, high cost of medical imaging equipment and lack of skilled professionals in the industry may impede this growth.

The global medical contrast agent market is segmented based on type, procedure, route of administration, indication, application, and region. Based on type, it is classified into barium-based contrast media, iodinated contrast media, gadolinium-based contrast media, and microbubble contrast media. Based on procedure, it is segmented into X-ray/computed tomography (CT), magnetic resonance imaging (MRI), and ultrasound. Based on route of administration, it is categorized into oral contrast media, injectable contrast media, rectal contrast media, and urethral contrast media.

Based on indication, it is divided into cardiovascular disorders, oncology, gastrointestinal disorders, musculoskeletal disorders, neurological disorders, and nephrological disorders. The application segment includes radiology, interventional radiology, and interventional cardiology. Based on region, the market is analyzed across North America, Europe, Asia Pacific, and LAMEA. These regions are further analyzed across the country level to determine the market size and forecast for each segment and sub-segment.

Comprehensive competitive analysis and profiles of major players, such as GE Healthcare, Bayer AG, Bracco Imaging S.P.A., Guerbet Group, Lantheus Medical Imaging, Nanopet Pharma GmbH, CMC Contrast AB, Daiichi Sankyo, Subhra Pharma Private Limited, and Spago Nanomedical AB, are provided in this report.

Key Benefits

The study provides an in-depth analysis, current trends, and future estimations of the global medical contrast agent market to elucidate the imminent investment pockets.
Extensive analysis is conducted by following key player positioning and monitoring the top competitors within the market framework.
It offers a quantitative analysis from 2017 to 2023 to enable the stakeholders to capitalize on the prevailing market opportunities.
Comprehensive analysis of all geographical regions is provided to determine the prevailing opportunities.
Key players are profiled and their strategies are analyzed thoroughly to understand the competitive outlook of the global market.

Medical Contrast Agent Market Key Segments:

By Type

Barium-based Contrast Media
Iodinated Contrast Media
Gadolinium-based Contrast Media
Microbubble Contrast Media

By Procedure

X-ray/Computed Tomography (CT)
Magnetic Resonance Imaging (MRI)
Ultrasound

By Route of Administration

Oral Contrast Media
Injectable Contrast Media
Rectal Contrast Media
Urethral Contrast Media

By Indication

Cardiovascular Disorders
Oncology
Gastrointestinal Disorders
Musculoskeletal Disorders
Neurological Disorders
Nephrological Disorders

By Application

Radiology
Interventional Radiology
Interventional Cardiology

By Region

North America
- U.S.
- Canada
- Mexico
Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
Asia-Pacific
- Japan
- China
- Australia
- India
- South Korea
- Rest of Asia-Pacific
LAMEA
- Brazil
- Turkey
- Saudi Arabia
- South Africa
- Rest of LAMEA

CHAPTER 1 INTRODUCTION

1.1. REPORT DESCRIPTION
1.2. KEY BENEFITS
1.3. KEY MARKET SEGMENTS
1.4. RESEARCH METHODOLOGY

1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools & models

CHAPTER 2 EXECUTIVE SUMMARY

2.1. CXO PERSPECTIVE

CHAPTER 3 MARKET OVERVIEW

3.1. MARKET DEFINITION AND SCOPE
3.2. KEY FINDINGS

3.2.1. Top investment pockets
3.2.2. Top winning strategies

3.3. MARKET SHARE ANALYSIS, 2016
3.4. PORTER’S FIVE FORCES ANALYSIS

3.4.1. MARKET DYNAMICS
3.4.2. Drivers
3.4.3. Restraints
3.4.4. Opportunities

CHAPTER 4 GLOBAL MEDICAL CONTRAST AGENT MARKET, BY TYPE

4.1. OVERVIEW

4.1.1. Market size and forecast

4.2. BARIUM-BASED CONTRAST MEDIA

4.2.1. Key market trends
4.2.2. Growth factors and opportunities
4.2.3. Market size and forecast

4.3. IODINATED CONTRAST MEDIA

4.3.1. Key market trends
4.3.2. Growth factors and opportunities
4.3.3. Market size and forecast

4.4. GADOLINIUM-BASED CONTRAST MEDIA

4.4.1. Key market trends
4.4.2. Growth factors and opportunities
4.4.3. Market size and forecast

4.5. MICROBUBBLE CONTRAST MEDIA

4.5.1. Key market trends
4.5.2. Growth factors and opportunities
4.5.3. Market size and forecast

CHAPTER 5 GLOBAL MEDICAL CONTRAST AGENT MARKET, BY PROCEDURE

5.1. OVERVIEW

5.1.1. Market size and forecast

5.2. X-RAY/COMPUTED TOMOGRAPHY (CT)

5.2.1. Market size and forecast

5.3. MAGNETIC RESONANCE IMAGING (MRI)

5.3.1. Market size and forecast

5.4. ULTRASOUND

5.4.1. Market size and forecast

CHAPTER 6 GLOBAL MEDICAL CONTRAST AGENT MARKET, BY BY ROUTE OF ADMINISTRATION

6.1. OVERVIEW

6.1.1. Market size and forecast

6.2. ORAL CONTRAST MEDIA

6.2.1. Market size and forecast

6.3. INJECTABLE CONTRAST MEDIAESONANCE IMAGING (MRI)

6.3.1. Market size and forecast

6.4. RECTAL CONTRAST MEDIA

6.4.1. Market size and forecast

6.5. URETHRAL CONTRAST MEDIA

6.5.1. Market size and forecast

CHAPTER 7 GLOBAL MEDICAL CONTRAST AGENT MARKET, BY INDICATION

7.1. OVERVIEW

7.1.1. Market size and forecast

7.2. CARDIOVASCULAR DISORDERS

7.2.1. Market size and forecast

7.3. ONCOLOGY

7.3.1. Market size and forecast

7.4. GASTROINTESTINAL DISORDERS

7.4.1. Market size and forecast

7.5. MUSCULOSKELETAL DISORDERS

7.5.1. Market size and forecast

7.6. NEUROLOGICAL DISORDERS

7.6.1. Market size and forecast

7.7. NEPHROLOGICAL DISORDERS

7.7.1. Market size and forecast

CHAPTER 8 GLOBAL MEDICAL CONTRAST AGENT MARKET, BY APPLICATION

8.1. OVERVIEW

8.1.1. Market size and forecast

8.2. RADIOLOGY

8.2.1. Market size and forecast

8.3. INTERVENTIONAL RADIOLOGY

8.3.1. Market size and forecast

8.4. INTERVENTIONAL CARDIOLOGY

8.4.1. Market size and forecast

CHAPTER 9 MEDICAL CONTRAST AGENT MARKET, BY GEOGRAPHY

9.1. OVERVIEW
9.2. NORTH AMERICA

9.2.1. Key market trends
9.2.2. Key growth factors and opportunities
9.2.3. Market size and forecast

9.2.3.1. U.S. market size and forecast
9.2.3.2. Canada market size and forecast
9.2.3.3. Mexico market size and forecast

9.3. EUROPE

9.3.1. Key market trends
9.3.2. Key growth factors and opportunities
9.3.3. Market size and forecast

9.3.3.1. Germany market size and forecast
9.3.3.2. France market size and forecast
9.3.3.3. UK market size and forecast
9.3.3.4. Italy market size and forecast
9.3.3.5. Spain market size and forecast
9.3.3.6. Rest of Europe market size and forecast

9.4. ASIA-PACIFIC

9.4.1. Key market trends
9.4.2. Key growth factors and opportunities
9.4.3. Market size and forecast

9.4.3.1. Japan market size and forecast
9.4.3.2. China market size and forecast
9.4.3.3. Australia market size and forecast
9.4.3.4. India market size and forecast
9.4.3.5. South Korea market size and forecast
9.4.3.6. Rest of Asia-Pacific market size and forecast

9.5. LAMEA

9.5.1. Key market trends
9.5.2. Key growth factors and opportunities
9.5.3. Market size and forecast

9.5.3.1. Brazil market size and forecast
9.5.3.2. Turkey market size and forecast
9.5.3.3. Saudi Arabia market size and forecast
9.5.3.4. South Africa market size and forecast
9.5.3.5. Rest of LAMEA market size and forecast

CHAPTER 10 COMPANY PROFILES

10.1. GE HEALTHCARE

10.1.1. Operating business segments
10.1.2. Business performance
10.1.3. Key strategic moves and developments

10.2. BAYER AG

10.2.1. Operating business segments
10.2.2. Business performance
10.2.3. Key strategic moves and developments

10.3. BRACCO IMAGING S.P.A.

10.3.1. Operating business segments
10.3.2. Business performance
10.3.3. Key strategic moves and developments

10.4. GUERBET GROUP

10.4.1. Operating business segments
10.4.2. Business performance
10.4.3. Key strategic moves and developments

10.5. LANTHEUS MEDICAL IMAGING

10.5.1. Operating business segments
10.5.2. Business performance
10.5.3. Key strategic moves and developments

10.6. NANOPET PHARMA GMBH

10.6.1. Operating business segments
10.6.2. Business performance
10.6.3. Key strategic moves and developments

10.7. CMC CONTRAST AB

10.7.1. Operating business segments
10.7.2. Business performance
10.7.3. Key strategic moves and developments

10.8. DAIICHI SANKYO

10.8.1. Operating business segments
10.8.2. Business performance
10.8.3. Key strategic moves and developments

10.9. SUBHRA PHARMA PRIVATE LIMITED

10.9.1. Operating business segments
10.9.2. Business performance
10.9.3. Key strategic moves and developments

10.10. SPAGO NANOMEDICAL AB

10.10.1. Operating business segments
10.10.2. Business performance
10.10.3. Key strategic moves and developments

With collective industry experience of about 200 years of its analysts and experts, Allied Market Research (AMR) encompasses most infallible research methodology for its market intelligence and industry analysis. We do not only engrave the deepest levels of markets but also sneak through its slimmest details for the purpose of our market estimates and forecasts. Our approach helps in building greater market consensus view for size, shape and industry trends within each industry segment. We carefully factor in industry trends and real developments for identifying key growth factors and future course of the market. Our research proceeds are the resultant of high quality data, expert views and analysis and high value independent opinions. Our research process is designed to deliver balanced view of the global markets and allow stakeholders to make informed decisions.

We offer our clients exhaustive research and analysis based on wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics and regional intelligence. Our in-house industry experts play instrumental role in designing analytic tools and models, tailored to the requirements of particular industry segment. These analytical tools and models sanitize the data & statistics and enhance the accuracy of our recommendations and advice. With AMR’s calibrated research process and 360` degree data-evaluation methodology, our clients are assured of receiving:

Consistent, valuable, robust and actionable data & analysis that can easily be referenced for strategic business planning
Technologically sophisticated and reliable insights through well audited and veracious research methodology
Sovereign research proceeds that present a tangible depiction of marketplace

With a strong methodology we are, therefore, confident that our research and analysis are most reliable and guarantees sound business planning.

Secondary research
We refer a broad array of industry sources for our secondary, which typically include; however, not limited to: Company SEC filings, annual reports, company websites, broker & financial reports and investor presentations for competitive scenario and shape of the industry

Patent and regulatory databases for understanding of technical & legal developments
Scientific and technical writings for product information and related preemptions
Regional government and statistical databases for macro analysis
Authentic new articles, web-casts and other related releases for market evaluation
Internal and external proprietary databases, key market indicators and relevant press releases for market estimates and forecast

Primary research
Our primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks and face-to-face interactions. We are also in professional corporate relations with various companies that allow us greater flexibility for reaching out industry participants and commentators for interviews and discussions, fulfilling following functions:

Validates and improves the data quality and strengthens research proceeds
Further develops analyst team’s market understanding and expertise
Supplies authentic information about market size, share, growth and forecasts

Our primary research interview and discussion panels are typically composed of most experienced industry members. These participants include; however, not limited to:

Chief executives and VPs of leading corporations specific to industry
Product and sales managers or country heads; channel partners and top level distributors; banking, investments and valuation experts Key opinion leaders (KOLs)

Analyst tools and models
AMR has developed set of analyst tools and data models to supplement and expedite the analysis process. Corresponding to markets, where there is significant lack of information and estimates, AMR’s team of experts and analyst develop specific analyst tools and industry models to translate qualitative and quantitative industry indicators into exact industry estimates. These models also allow analysts to examine the prospects and opportunities prevailing in the market to accurately forecast the course of the market.

Online Only ~~$3,456~~ $3,110 Data Pack/Excel ~~$3,840~~ $3,456 Single User License ~~$5,370~~ $4,833 Five User License ~~$6,450~~ $5,805 Enterprise User License ~~$8,995~~ $8,096

* Taxes/Fees, If applicable will be
added during checkout. All prices in USD.

Call us on
( U.S. - Canada toll free )
+1-800-792-5285,
Int'l : +1-503-894-6022
( Europe )
+ 44-845-528-1300
Drop us an email at
help@alliedmarketresearch.com